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AbsTrACT 
Aims There is no internationally accepted grading 
system for lung adenocarcinoma despite the new WHO 
classification. The architectural grade, the Kadota grade 
and the Sica score were evaluated and compared with 
overall (OS) and disease-free survival (DFS).
Methods Comprehensive histological subtyping was 
used in a series of resected stage I lung adenocarcinoma 
to identify subtypes of adenocarcinomas, the 
architectural grade, the Kadota grade, the Sica grade, 
the mitotic count, nuclear atypia, the presence of 
lymphovascular, vascular and airway propagation, 
necrosis, and micropapillary or solid growth pattern in 
any percentage. Statistical models fitted included Kaplan-
Meier estimates and Cox proportional hazard regression 
models.
results 261 stage I adenocarcinomas were included. 
The 5-year survivals of different subtypes were as 
follows: lepidic (n=40, OS: 92.5%; DFS 91.6%), acinar 
(n=54, OS: 81.8%; DFS: 68.6%), papillary (n=49, OS: 
73.6%; DFS: 61.0%), solid (n=95, OS: 64.7%; DFS: 
57.8%) and micropapillary (n=23, OS: 34.8%; DFS: 
33.5%). Concerning the architectural grade, there 
were significant differences between OS and DFS of 
low and intermediate (pOS=0.005, pDFS<0.001), low 
and high (pOS<0.001, pDFS<0.001) and intermediate 
and high grades (pOS=0.002, pDFS<0.001). Low-
grade and intermediate grade tumours did not differ in 
survival according to Kadota grade and Sica grade. In 
the multivariable model, architectural grade was found 
to be an independent prognostic marker. In another 
model, architectural pattern proved to be superior to 
architectural grade.
Conclusions Of the three grading systems compared, 
the architectural grade makes the best distinction 
between the outcome of low-grade, intermediate-grade 
and high-grade stage I adenocarcinomas.
bACkgrOund
The WHO introduced a new classification of lung 
cancers in 2015.1 The new classification follows the 
suggestions of the International Multidisciplinary 
Lung Adenocarcinoma Classification proposed 
by the International Association for the Study of 
Lung Cancer (IASLC), American Thoracic Society 
(ATS) and European Respiratory Society (ERS). 
The non-invasive growth pattern previously called 
bronchioloalveolar carcinoma is now called lepidic 
pattern.2 In situ adenocarcinoma (AIS) and mini-
mally invasive adenocarcinoma (MIA) were intro-
duced. The former has 100%3–6 and the latter has 
nearly 100% overall survival (OS).7–9 The subtypes 
of invasive adenocarcinoma are based on the 
predominant growth pattern, and include lepidic, 
acinar, papillary, solid and micropapillary carci-
nomas (figure 1). Lepidic carcinomas have been 
correlated with better prognosis,10–12 whereas solid 
and micropapillary carcinomas are at the other 
end of the spectrum and have an unfavourable 
prognosis.13–15
Although grading is an essential part of histo-
pathology reports in almost all carcinomas, there 
is no internationally accepted grading system for 
lung adenocarcinomas. Architectural grade, which 
is the most frequently referred one, is based on the 
predominant growth pattern of invasive carcinoma. 
It contains three grades: low (lepidic), intermediate 
(acinar and papillary) and high grade (solid and 
micropapillary).16 Despite the fact that most lung 
adenocarcinomas have mixed growth patterns, the 
architectural grade of these tumours refers to the 
predominant growth pattern only, in keeping with 
the IASLC/ATS/ERS and WHO classifications. A 
lepidic carcinoma (named after its predominant 
pattern) may have solid or micropapillary parts too, 
and this combination could result in a more aggres-
sive biological behaviour.
The Sica grade is similar to the Gleason score 
of prostatic adenocarcinoma. The advantage of 
this system is that it takes both the predominant 
and the second most common growth patterns 
into account. Both are scored and the sum of these 
points refer to the clinical behaviour.17 18 The orig-
inal grading system does not exactly match the new 
IASLC/ATS/ERS classification because of the use 
of the term bronchioloalveolar carcinoma and its 
mucinous variant.18 Therefore, we used the modi-
fied scores19 based on the new classification, and 
these are referred to as Sica grade throughout this 
work. Lepidic pattern gets 1, acinar and papillary 2, 
and solid and micropapillary 3 points. AIS, with its 
2 points, means the low-grade group. Carcinomas 
with 3–4 points make up the intermediate-grade 
and those with 5–6 points form the high grade 
group.
Kadota and coworkers20 suggested a grading 
system that combines the predominant growth 
pattern and the mitotic count in 10 high-power 
fields (HPF). In this system low grade includes 
lepidic invasive carcinoma along with acinar and 
papillary carcinomas with low mitotic counts (0–1 
mitosis/10 HPFs).
Our aim was to evaluate and compare the prog-
nostic value of architectural grade, the Sica grade 
and the Kadota grade, and look for the one that 
may best reflect prognosis in early-stage adenocar-
cinomas where adjuvant systemic therapy is gener-
ally not given to patients having clear margins.21
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MeThOds
Patients with a diagnosis of primary pulmonary adenocarcinoma 
in stage IA or IB according to the 7th Edition of Tumour, Node, 
Metastasis Classification1 who were operated on at the Divi-
sion of Thoracic Surgery, Department of Surgery, University of 
Szeged, between 2004 and 2013 were selected for the cohort 
to be analysed. Accordingly, these tumours were not larger than 
5 cm, localised only in the lung, had no pleural involvement 
and lymph node, or distant metastasis. Cases with multicentric, 
metachronous or metastatic disease, positive surgical margin, 
lung cancer surgery in the preceding 2 years, preoperative 
chemotherapy, unavailable H&E-stained slides, perioperative 
death (within 30 days following surgery) and vascular inva-
sion were excluded. Clinical information concerning gender, 
age, smoking habits, tumour localisation, type of surgery and 
follow-up data was collected from medical charts. The follow-up 
of patients consisted of three monthly chest X-ray examina-
tions in the first 2 years, then six monthly until the fifth year. 
Chest CT was performed every 6 months for the first 2 years. 
In case of any progression, chest CT and abdominal ultraso-
nography were included. The follow-up period ended on 31 
August 2015.
Surgically resected specimens had originally been fixed in 
neutral buffered formalin for at least 24 hours. As a routine, 
3–4 μm thick sections made from the formalin-fixed and 
paraffin-embedded tissue blocks were stained with H&E. As a 
special stain, orcein was used for highlighting elastic fibres17 22 
to assess intact stromal architecture in lepidic growth pattern. 
All tumour-containing slides were reviewed by two patholo-
gists (TZ and LT) who were blinded to patients’ outcomes. 
The number of slides per case depended on tumour size as one 
section had been generally taken for each centimetre of largest 
tumour dimension. Any discrepancies between the evaluation 
of the two pathologists were resolved via consensus using a 
multiheaded microscope. The histological identification of 
lung adenocarcinoma was based on the current WHO classi-
fication.1 23 The most frequent and the second most frequent 
pattern components were both defined. The subtype of adeno-
carcinoma was determined by the growth pattern with the 
highest percentage. Tumours were grouped by architectural 
grade as of low (lepidic), intermediate (acinar and papillary) 
or high (solid, micropapillary) grade. The Sica scores were 
calculated by evaluation of the predominant and the second 
most common growth pattern. The Kadota grade was derived 
from the observation of the predominant growth pattern and 
the mitotic count in 10 HPFs. For each case, 30 HPFs were 
counted for mitotic activity using an Olympus BX43 (Olympus, 
Tokyo, Japan) microscope at 400× magnification (objective 
40×, field area=0.237 mm2), and the average rounded number 
of mitoses per 10 HPFs was recorded. The Kadota and Sica 
grading systems include AIS and MIA, but the architectural 
grade refers only to the invasive carcinomas and not the prein-
vasive or minimally invasive ones. In order to overcome this 
discrepancy and make the comparison of the grading systems 
limited to the same set of early-stage tumours, AIS and MIA 
were excluded from the study. As among the Sica grades, the low 
grade is composed exclusively of cases we excluded; we used 
the scores rather than the grades for verifying differences in 
prognosis.
Besides the grading systems, the following histological factors 
were re-evaluated: nuclear atypia, presence of lymphatic inva-
sion, airway spread and necrosis. Nuclear atypia was graded 
as low (monomorphic nucleus in size and shape) or high (large 
differences in the diameter of nuclei, multinucleated tumour 
cells). Lymphatic invasion was deemed present when at least 
one cluster of tumour cells was seen in an endothelium-lined, 
preformed lumen without red blood cells. Airway spread was 
detected if clusters of tumour cells were seen in the peritumorous 
alveoli, in bronchioli or bronchi. Tumour size was assessed by 
standard gross measurement.
The presence of a solid or a micropapillary component was 
always noted, regardless of the predominant growth pattern and 
its percentage. Variants of adenocarcinoma like invasive muci-
nous, mixed invasive mucinous/non-mucinous, colloid, fetal 
and enteric were excluded from the present study due to the 
distinctly different morphology and rarity.
OS and disease-free survival (DFS) were assessed using 
Kaplan-Meier estimates. The patients were followed from the 
date of surgery until the time of recurrence or tumour-related 
death. The events considered were therefore manifestations of a 
recurrence and death of the patient due to lung cancer, respec-
tively. Patients alive without recurrence and patients dying from 
other causes were censored at the time of the last follow-up and 
death, respectively. The receiver operating characteristic (ROC) 
curve model was used to identify a cut-off value between low 
and high mitotic counts. Mann-Whitney U model was applied 
for seeking difference between the mitotic rate of surviving 
patients and patients dying of tumour progression. The log-rank 
test was used for pairwise comparisons. All statistical tests were 
two-sided, and p<0.05 values were considered statistically 
significant. The parameters found significant in the univari-
able model were entered in multivariable Cox proportional 
hazard model to identify factors of independent prognostic 
significance. Statistical models were fitted using SPSS Statistics 
V.22.0 software.
Figure 1 Architectural patterns of pulmonary adenocarcinoma: 
(A) lepidic growth pattern (HE, 20×); (B) acinar carcinoma (HE, 20×); 
(C) papillary carcinoma (HE, 20×); (D) solid carcinoma (HE, 20×); (E) 
micropapillary carcinoma (HE, 20×); and (F) papillary carcinoma with 
micropapillary features (orcein-haematoxylin stain, 20×).
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This retrospective study was approved by the institutional 
ethical committee of the Albert Szent-Györgyi Clinical Centre of 
the University of Szeged.
resulTs
Altogether, 327 patients matching the stage, type and subtype 
criteria described in the methods were operated on at the Depart-
ment of Surgery, University of Szeged, between 2004 and 2013. 
There was no clinical information about 35 surviving patients 
and about 31 deceased patients. In three cases, slides were not 
available. Patients with these missing data were excluded from 
the model. Accordingly, 261 resected adenocarcinomas were 
examined in this retrospective study: 159 cases were of stage IA 
and 102 of stage IB.
The clinical features of all 261 patients are shown in table 1.
The patients’ median age was 61.7 years (range: 36–83). The 
gender distribution was close to equal (50.9% vs 49.1%). There 
were 90.8% (n=237) lobar or greater resections and 9.2% 
(n=24) sublobar resections. Lung adenocarcinoma was more 
frequently right-sided (61.3%; n=160). More than two-thirds 
of the patients had history of smoking in the clinical anamnesis 
(80.5%; n=210).
All the available H&E-stained slides were reviewed (median: 
3 tumour slides; range: 2–10 tumour slides per patient).
The distribution of subtypes of adenocarcinomas and the 
results of predominant and second most common growth 
patterns are summarised in table 2.
The median follow-up was 52.3 months (range: 1.5–150.3 
months). The 5-year OS and DFS of adenocarcinoma subtypes 
are shown in table 3. We evaluated the architectural grade by 
using Kaplan-Meier curves (figure 2). There were significant 
differences between the OS estimates of low-grade (lepidic) and 
intermediate-grade (acinar and papillary), low-grade and high-
grade (solid and micropapillary), and intermediate-grade and 
high-grade adenocarcinomas. Similarly, there were significant 
differences in DFS between low-grade and intermediate-grade, 
low-grade and high-grade, and intermediate-grade and high-
grade adenocarcinomas. Among cases with a high architectural 
grade, a significant difference in both OS and DFS was also 
detectable between solid and micropapillary carcinomas, the 
latter being the worst.
According to the fourth edition of the WHO classification of 
lung tumours, the cribriform pattern is a subgroup of the acinar 
growth pattern. In our study eight cribriform adenocarcinomas 
were identified, with equal OS and DFS estimates of 75%.
With the Kadota grade (figure 3), a significant difference in 
both OS and DFS was seen between low-grade and high-grade, 
and between intermediate-grade and high-grade adenocarci-
nomas. Low-grade and intermediate-grade tumours showed no 
such difference. Regarding the Sica scores, significant differences 
were detected in OS and DFS (figure 4): there were significant 
differences between survival estimates of scores of 3 and 5, 3 
and 6, 4 and 5, and 4 and 6, but there was no such difference 
between scores of 3 and 4 and 5 and 6.
By using the mitotic rate per 10 HPFs, we attempted to identify 
a group of tumours with a high mitotic rate that would be associ-
ated with poor prognosis and a group with a low mitotic rate asso-
ciated with better prognosis. We used the ROC curve model for the 
determination of an optimal cut-off value for mitotic count. Low 
sensitivity (52.0%–74.0%) and specificity (44.7%–57.5%) values 
were found regardless of the mitotic cut-off value. The Mann-
Whitney U model revealed a significant difference between the 
Table 1 Clinical features of patients
Clinical variables n (%)
Age, years
 Median (range) 61.7 (36.9–83.5)
Gender
 Female 133 (50.9%)
 Male 128 (49.1%)
Smoking
 Never 51 (19.5%)
 Ever 210 (80.5%)
Laterality
 Right 160 (61.3%)
 Left 101 (38.7%)
Surgical resection
 Lobar 237 (90.8%)
 Sublobar 24 (9.2%)
Stage
 IA 159 (60.9%)
 IB 102 (39.1%)
Adjuvant systemic therapy
 Yes 71 (27.2%)
 No 190 (72.8%)
Tumour-related death
 IA 44 (16.8%)
 IB 23 (8.8%)
Tumour recurrence
 IA 62 (23.7%)
 IB 33 (12.6%)
Table 2 Distribution of primary and secondary growth patterns of the series
Total Predominant growth pattern
n (%) lepidic (%) Acinar (%) Papillary (%) solid (%) Micropapillary (%)
 261 40 (15.3) 54 (20.7) 49 (18.7) 95 (36.5) 23 (8.8)
Second most common 
growth pattern (%)
None 94 (36.2) – 19 (7.2) 14 (5.3) 58 (22.2) 3 (1.1)
Lepidic 25 (9.5) – 5 (1.9) 14 (5.3) 1 (0.3) 5 (1.9)
Acinar 64 (24.5) 21 (8.0) – 13 (5.0) 24 (9.2) 6 (2.2)
Papillary 48 (18.4) 16 (6.1) 19 (7.2) – 5 (1.9) 8 (3.0)
Solid 11 (4.2) 0 (0) 8 (3.0) 2 (0.6) – 1 (0.3)
Micropapillary 19 (7.2) 3 (1.1) 3 (1.1) 6 (2.2) 7 (2.7) –
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mitotic count of surviving patients and patients dying from tumour 
progression (p=0.042). The median mitotic counts of these two 
groups of patients were 6 and 8, respectively.
Significant 5-year OS differences were identified (table 3) 
according to low or high nuclear atypia (p=0.04), mitotic 
rate with 5 mitosis/10 HPFs cut-off value (p=0.049) and solid 
growth pattern in any percentage (p=0.03).
In stage IA, a significant difference was observed between OS 
of tumours with presence or absence of airway spread (p=0.038) 
and micropapillary pattern in any percentage (p=0.027). 
Airway spread was detected in 98 cases, including eight tumours 
removed by sublobectomies, and six patients with this feature 
received adjuvant systemic chemotherapy. Survival was not influ-
enced by necrosis.
A multivariable Cox proportional hazard model was applied for 
OS, including architectural grade, Kadota grade and Sica score. 
Architectural grade was found to be the only independent prog-
nostic marker (pOS=0.002, HR: 7.21, 95% CI 2.04 to 25.43; 
pDFS=0.004, HR: 3.62, 95% CI 1.51 to 8.67). We also explored 
a Cox model for OS, including architectural grade and subtype. 
Regarding OS, subtype was identified as an independent prog-
nostic marker (pOS=0.039, HR: 1.9, 95% CI 1.03 to 3.53).
disCussiOn
Although grade is a generally recognised prognostic factor of 
malignant tumours and grading is a standard component of their 
pathology reports, there is no internationally accepted, well-studied 
Table 3 Morphological variables and their relation to overall survival 
(OS) and disease-free survival (DFS)
Morphological 
variables  n  %
5-year 
Os  p
5-year 
dFs  p
Nuclear atypia 0.04 0.022
Low 22 8.4 90.1 90.9
High 239 91.6 71.5 61.4
Mitotic rate (cut-off=5 
M/10 high-power field)
0.049 0.158
Low 123 47.1 80.2 69.2
High 138 52.9 68.1 61.7
Necrosis 0.352 0.223
Presence 125 47.8 68.5 60.7
Absence 136 52.2 78.6 69.4
Lymphatic invasion 0.088 0.372
Presence 61 23.3 64.4 60.1
Absence 200 76.7 75.6 67.2
Airway spread* 0.157 0.207
Presence 98 37.5 65.7 59.4
Absence 163 62.5 77.7 68.0
Micropapillary pattern* 0.214 0.408
Presence 90 34.5 68.1 58.7
Absence 171 65.5 76.8 67.8
Solid pattern 0.03 0.178
Presence 128 49.0 69.3 59.3
Absence 133 51.0 78.1 70.2
Histological subtype <0.001 <0.001
Lepidic 40 15,3 92.5 91.6
Acinar 54 20.7 81.8 68.6
Papillary 49 18.7 73.6 61.0
Solid 95 36.5 64.7 57.8
Micropapillary 23 8.8 34.8 33.5
*Significant OS differences were found between tumours with and without airway 
spread (p=0.038) and micropapillary pattern in any percentage (p=0.027) in stage 
IA.
Figure 2 (A) Overall survival (OS) and (B) disease-free survival 
(DFS) estimates of architectural grade: low grade (n=40; OS=92.5%, 
DFS=95.2%), intermediate grade (n=99; OS=78.5%, DFS=65.3%) and 
high grade (n=122; OS=60.3%, DFS=54.1%). Significant differences 
were found between low and intermediate grade (pOS=0.005; 
pDFS <0.001), low and high grade (pOS <0.001; pDFS <0.001) and 
intermediate and high grade (pOS=0.002; pDFS <0.001).
Figure 3 (A) Overall survival (OS) and (B) disease-free survival 
(DFS) estimates of Kadota grade: low grade (n=75; OS=87.9%, 
DFS=79.3%), intermediate grade (n=64; OS=80.3%, DFS=65.9%) and 
high grade (n=122; OS=61.7%, DFS=54.1%). Significant differences 
were found between low and high grade (pOS<0.001; pDFS<0.001) 
and intermediate and high grade (pOS=0.009; pDFS=0.031), but not 
such a difference was observed between low and intermediate grade 
(pOS<0.187; pDFS<0.104).
Figure 4 (A) Overall survival (OS) and (B) disease-free survival 
(DFS) estimates of Sica scores: score of 3 (n=61; OS=82.4%, 
DFS=78.1%), score of 4 (n=66; OS=85.1%, DFS=74.1%), score of 5 
(n=62; OS=67.3%, DFS=57.5%) and score of 6 (n=72; OS=59.6%, 
DFS=51.0%). There were significant differences between survival 
estimates of scores of 3 and 5 (pOS=0.025; pDFS=0.030), 3 and 6 
(pOS=0.002; pDFS=0.002), 4 and 5 (pOS=0.020; pDFS=0.001), and 4 
and 6 (pOS=0.002; pDFS=0.008), but there was no such difference 
between scores of 3 and 4 (pOS=0.923; pDFS=0.734) and 5 and 6 
(pOS=0.42; pDFS=0.29).
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grading system for lung adenocarcinomas. The aim of this study 
was to evaluate and compare the prognostic value of accessible 
grading systems for stage IA and IB lung adenocarcinomas.
For OS as endpoint, the prognostic variables found significant 
in the univariable model were the following: subtype of adeno-
carcinoma, architectural grade, Kadota grade, Sica grade, nuclear 
atypia, mitotic count and solid phenotype in any percentage. In 
cases of stage IA, airway spread and micropapillary pattern in 
any percentage were found to be significant too (table 3).
As concerns the architectural grade, significant differences 
were found between the OS and DFS of patients between each 
grade, both in stage IA and stage IB. In the high-grade group, 
solid and micropapillary adenocarcinomas also demonstrated 
significantly different OS and DFS.
Kadota and coworkers launched a grading system combining 
architectural features and the mitotic count in 10 HPFs20. In this 
novel grading system, adenocarcinomas with an intermediate 
architectural grade (acinar or papillary) with a low (<3/10 HPFs) 
mitotic count are classified as of low grade. The low grade also 
includes AIS, MIA and lepidic carcinoma, which do not fully 
coincide with the criteria of invasive adenocarcinoma. In order 
to maintain comparability between the grades, AIS and MIA were 
excluded from the study. Consistent with the results of Kadota and 
coworkers, we found no difference in the survival of low-grade 
and intermediate-grade groups either in stage IA or stage IB.
A special focus was given to mitotic counts with emphasis on 
finding a cut-off value distinguishing between tumours with a 
low mitotic count and a better prognosis versus tumours with a 
high mitotic count and a worse prognosis. The ROC curve model 
showed that the specificity and the sensitivity of mitotic count 
are low, and there is no optimal cut-off value for the mitotic 
count in 10 HPFs. A high mitotic rate does not necessarily confer 
bad prognosis. The Mann-Whitney U model however revealed a 
significant difference in the mitotic count between patients alive 
at the last follow-up and patients dead of disease. The median 
mitotic rate of the latter was higher. The literature about the 
prognostic role of mitotic activity is controversial. Kadota et 
al found that only mitotic count had a significant association 
with the risk of recurrence in a multivariable model including 
nuclear diameter, prominence of nucleoli and mitotic count. 
After adjusting for clinicopathological factors including gender, 
stage, pleural/lymphovascular invasion, necrosis and architec-
tural/mitotic grade (ie, the Kadota grade), mitotic count was not 
an independent predictor of recurrence.19 Duhig et al24 have 
identified mitotic index as the only independent prognostic 
marker, which was more closely associated with outcome than 
either the pathological T stage or the IASLC/ATS/ERS architec-
ture-based classification. Consistent with our results, Barletta 
and coworkers25 could not identify mitotic count as a significant 
prognostic variable. To assess mitotic activity, Kadota et al as 
well as Duhig et al had evaluated 50 HPFs, Barletta et al counted 
between 30 and 50 HPFs, and the present study used 30 HPFs 
to derive the average number of mitoses in 10 HPFs. Although 
there was a difference in the number of HPFs assessed in these 
studies, and this might have contributed to the differences in 
their conclusions, it is unlikely that this factor has played a major 
role in the discrepancy of the results.
Sica et al introduced a grading system based on predom-
inant and second most common growth pattern. The impor-
tance of a secondary growth pattern is clear if there is a lepidic 
tumour with micropapillary or solid features. Recent studies 
have revealed that the presence of a micropapillary or a solid 
pattern in any percentage is associated with poor overall and 
recurrence-free survival, and this is in keeping with our results 
too.13 14 26 27 As the Sica grade also covers AIS and MIA, and 
the low grade is composed exclusively of cases we excluded 
for maintaining comparability by restricting the evaluation to 
invasive adenocarcinomas, we used the scores rather than the 
grades. In the present study on stage I invasive adenocarci-
nomas, a significant difference in OS and DFS was identified 
between survival estimates of Sica scores of 3 and 5, 3 and 6, 4 
and 5, and 4 and 6, but there was no such difference between 
scores of 3 and 4 as well as 5 and 6, which supports the stage 
grouping of these scores into intermediate and high grades, 
respectively. (In a previous analysis, where the low-grade cases 
including AIS and MIA were also considered (data not shown), 
there was no significant difference in OS and DFS between low 
and intermediate Sica grade tumours, such a difference mani-
fested only for low-grade vs high-grade, and intermediate-grade 
vs high-grade tumours.)
By using a multivariable model including architectural grade, 
Kadota grade and Sica score, the architectural grade was identified 
as an independent prognostic factor. A multivariable Cox regres-
sion model including architectural grade and subtypes of adeno-
carcinoma revealed that the subtype is superior to architectural 
grade. Consistent with our result, Tsuta and coworkers have found 
that subtyping of adenocarcinoma is a better prognostic factor than 
histological grouping28. Our findings suggest that the Kadota and 
the Sica grading systems cannot divide stage I adenocarcinomas 
into three groups with different outcomes. According to our 
results, the architectural grade is the one that best describes the 
prognosis of adenocarcinomas, at least in stage I.
We also pointed out that in the high-grade group, there is a 
remarkable difference between solid adenocarcinoma with a 
poor prognosis and micropapillary carcinoma with the worst 
prognosis both in stages IA and IB. The reason for this could 
be the fact that solid and especially micropapillary carcinomas 
show a greater tendency to give lymph node and distant metas-
tasis.26 We also found a worsening of the survival data in other 
subtypes of lung adenocarcinoma whenever solid or micropapil-
lary features were present.
Finally, a few limitations of this study should be mentioned. The 
subjectivity in estimating the predominant pattern of pulmonary 
adenocarcinomas could bias the architectural grade itself. With 
training, this categorisation has been reported to improve.29 Such a 
subjectivity and less than perfect reproducibility is the hallmark of 
several grading systems, including the histological grading of breast 
carcinomas30 or the Gleason grading of prostate cancer,31 both of 
which are established prognosticators of the relevant malignancies. 
Although subjectivity in establishing the architectural grade may 
diminish its prognostic strength, our data, in keeping with other 
publications,16–19 also suggest that this prognostic role is neverthe-
less present. The architectural grade refers to invasive adenocar-
cinoma only, and the Kadota grade and Sica score refer to AIS, 
MIA and invasive adenocarcinoma together. In order to limit the 
comparisons to the same set of tumours, and avoid a bias from the 
influence of stage 0 on grade, we excluded AIS and MIA, which 
could be considered a further limitation of our work, although we 
consider this one of its strengths. Regarding nuclear atypia, only 
the nuclear size and shape uniformity were evaluated in this work. 
However Nakazato and coworkers32 proposed a nuclear grading 
based on measuring nuclear area and dimension.33 The propor-
tions of growth patterns can be diagnosed only on resected spec-
imens; therefore, only resected specimens were included in this 
study, and some tumours were therefore even not considered for 
analysis. This is due to the fact that biopsy specimens are generally 
too small for an accurate assessment of the predominant pattern 
and therefore grading.
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In summary, we have evaluated three grading systems in stage 
I pulmonary adenocarcinomas — the architectural grade, the 
Kadota grade and the Sica grade — and have compared them 
for their ability to reflect OS and DFS. To our knowledge, these 
grading systems have never been compared according to their 
prognostic value. Tumours with a low or intermediate grade 
according to the Kadota and Sica grades showed no differ-
ence in survival. Despite the supposed accuracy of Kadota and 
Sica grades, only the architectural grade could separate the 
outcome of low-grade, intermediate-grade and high-grade inva-
sive adenocarcinomas. Tumour differentiation as reflected by 
their grade is an important prognosticator in many cancers. On 
the basis of the presented results suggesting the superiority of the 
architectural grade over the others, we propose its use in routine 
histopathology reports of lung adenocarcinomas in keeping with 
the current WHO recommendation.
Take home messages
 ► Of available grading systems of pulmonary adenocarcinomas, 
the architectural grade based on the predominant growth 
pattern is the best for characterising disease outcome in early 
stage, that is, stage I.
 ► We propose its use in routine histopathology reports of 
lung adenocarcinomas in keeping with the current WHO 
recommendation.
 ► The two alternative grading systems of Kadota and Sica 
failed to make a difference between overall and disease-
free survival of low-grade and intermediate-grade 
adenocarcinomas.
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